Antibody treatment added to HIV meds for early HIV
Part of Immune system & allergy, Infections clinical trials.
This Phase 2 trial tests whether adding long-acting HIV antibodies to standard HIV treatment (ART) can help control HIV in people who started ART soon after getting infected. It also checks how safe the antibody treatment is and how well it works over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 60 years old
- You must be able to sign consent and attend regular study visits with blood tests
- You must have started HIV treatment within 6 months of becoming infected
- You must have strong immune health: recent CD4 count above 500 (or CD4:CD8 ratio above 1)
- You must be on HIV treatment that includes an integrase inhibitor or a boosted protease inhibitor at enrollment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
This trial tests two lab-made antibodies that may help control HIV without daily pills. It is for people who started HIV treatment very early and now take a break from their regular meds under close monitoring.
This study tests whether giving special HIV-fighting antibodies along with starting standard HIV medicine soon after infection can help you reach “HIV remission.” It may reduce or delay the return of detectable virus, but you must be willing to follow close monitoring and specific study steps.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This Phase 3 study looks at antiretroviral treatment (HIV medicines) for adults with either recent (acute) or long-term (chronic) HIV. It’s designed to see how well and safely ongoing HIV treatment works, and it may help you get structured care and monitoring.
This study tests a combination of an HIV vaccine and an antibody infusion to see if your immune system can control HIV without daily pills. You would temporarily stop your HIV medication under close monitoring and restart if needed.
Hear when a new HIV/AIDS and Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.